Reviva Pharmaceuticals (RVPH) Competitors $1.18 -0.02 (-1.67%) (As of 12:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RVPH vs. ATOS, PBYI, GOSS, CHRS, FTLF, ELUT, CADL, MCRB, BDTX, and NBTXShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Atossa Therapeutics (ATOS), Puma Biotechnology (PBYI), Gossamer Bio (GOSS), Coherus BioSciences (CHRS), FitLife Brands (FTLF), Elutia (ELUT), Candel Therapeutics (CADL), Seres Therapeutics (MCRB), Black Diamond Therapeutics (BDTX), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Atossa Therapeutics Puma Biotechnology Gossamer Bio Coherus BioSciences FitLife Brands Elutia Candel Therapeutics Seres Therapeutics Black Diamond Therapeutics Nanobiotix Atossa Therapeutics (NASDAQ:ATOS) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Do analysts rate ATOS or RVPH? Atossa Therapeutics currently has a consensus target price of $6.75, indicating a potential upside of 423.26%. Reviva Pharmaceuticals has a consensus target price of $15.50, indicating a potential upside of 1,191.67%. Given Reviva Pharmaceuticals' higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Atossa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Reviva Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ATOS or RVPH more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Atossa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atossa TherapeuticsN/A -35.74% -33.51% Reviva Pharmaceuticals N/A N/A -252.53% Which has preferable valuation & earnings, ATOS or RVPH? Atossa Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa TherapeuticsN/AN/A-$30.09M-$0.22-5.86Reviva PharmaceuticalsN/AN/A-$39.26M-$1.11-1.08 Which has more risk and volatility, ATOS or RVPH? Atossa Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Does the MarketBeat Community prefer ATOS or RVPH? Atossa Therapeutics received 215 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.00% of users gave Reviva Pharmaceuticals an outperform vote while only 64.93% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformAtossa TherapeuticsOutperform Votes23764.93% Underperform Votes12835.07% Reviva PharmaceuticalsOutperform Votes2288.00% Underperform Votes312.00% Do insiders & institutionals believe in ATOS or RVPH? 12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 7.6% of Atossa Therapeutics shares are held by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer ATOS or RVPH? In the previous week, Atossa Therapeutics and Atossa Therapeutics both had 2 articles in the media. Atossa Therapeutics' average media sentiment score of 1.89 beat Reviva Pharmaceuticals' score of 0.43 indicating that Atossa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Atossa Therapeutics Very Positive Reviva Pharmaceuticals Neutral SummaryAtossa Therapeutics and Reviva Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.13M$6.74B$5.22B$8.91BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-1.084.6785.2013.34Price / SalesN/A354.421,473.6986.84Price / CashN/A22.8835.2835.09Price / Book6.005.614.914.96Net Income-$39.26M$152.02M$117.66M$224.28M7 Day Performance7.14%3.31%2.85%1.98%1 Month Performance22.76%-1.52%1.78%9.78%1 Year Performance-68.71%31.57%35.88%29.97% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.4212 of 5 stars$1.18-1.7%$15.50+1,213.6%-68.7%$39.46MN/A-1.065Short Interest ↑ATOSAtossa Therapeutics1.6102 of 5 stars$1.29-0.8%$6.75+423.3%+67.1%$162.28MN/A-5.918Positive NewsPBYIPuma Biotechnology4.2291 of 5 stars$3.25-4.1%$7.00+115.4%-14.7%$159.54M$235.60M6.77185GOSSGossamer Bio4.1498 of 5 stars$0.70+0.6%$9.20+1,209.4%-13.7%$159.21M$105.32M-2.18180Positive NewsCHRSCoherus BioSciences3.8042 of 5 stars$1.36+11.5%$6.13+350.4%-40.4%$156.69M$257.24M-17.00246Options VolumeNews CoverageGap UpFTLFFitLife Brands3.4139 of 5 stars$33.18-1.6%$40.00+20.6%+68.4%$152.56M$62.76M19.9620Short Interest ↑ELUTElutia3.4014 of 5 stars$4.36+5.3%$10.00+129.4%+110.7%$150.68M$24.75M-1.59180Positive NewsCADLCandel Therapeutics2.6614 of 5 stars$4.63-1.7%$11.00+137.6%+407.8%$150.36M$120,000.00-2.7760Short Interest ↑MCRBSeres Therapeutics3.8896 of 5 stars$0.87-10.9%$5.08+482.0%-13.4%$149.14M$126.32M-3.83233BDTXBlack Diamond Therapeutics3.0277 of 5 stars$2.60-1.9%$15.50+496.2%+9.7%$147.12MN/A-1.9590Short Interest ↓Positive NewsNBTXNanobiotix2.8269 of 5 stars$3.12-3.4%$11.50+268.6%-46.0%$147.06M$36.22M0.00100Gap Down Related Companies and Tools Related Companies ATOS Alternatives PBYI Alternatives GOSS Alternatives CHRS Alternatives FTLF Alternatives ELUT Alternatives CADL Alternatives MCRB Alternatives BDTX Alternatives NBTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RVPH) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
